| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/14/2006 | WO2006094705A1 Ophthalmic uses of s1p receptor modulators |
| 09/14/2006 | WO2006094704A2 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/14/2006 | WO2006094703A1 Use of an antagonist of epac for treating human cardiac hypertrophy |
| 09/14/2006 | WO2006094691A1 PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS |
| 09/14/2006 | WO2006094682A1 Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds |
| 09/14/2006 | WO2006094681A1 Non-fibrous transdermal therapeutic system and method for its production |
| 09/14/2006 | WO2006094674A1 Nmda receptor antagonists in the medical intervention of metabolic disorders |
| 09/14/2006 | WO2006094664A1 Endoparasiticide |
| 09/14/2006 | WO2006094662A1 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal |
| 09/14/2006 | WO2006094639A1 Pyridine-2-carboxamide derivatives as mglur5 antagonists |
| 09/14/2006 | WO2006094626A1 Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
| 09/14/2006 | WO2006094604A1 Tetrahydro- and dihydroquinazolinones |
| 09/14/2006 | WO2006094600A1 Substituted tetrahydropyrroloquinoline derivatives as kinase modulators, especially tyrosine kinase and raf kinase modulators |
| 09/14/2006 | WO2006094507A1 Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
| 09/14/2006 | WO2006094414A1 Non invasive method for prevention and treatment of cancer |
| 09/14/2006 | WO2006094406A1 Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof |
| 09/14/2006 | WO2006094395A1 Preparation of acid addition salts of amine bases by solid phase-gas phase reactions |
| 09/14/2006 | WO2006094385A1 Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| 09/14/2006 | WO2006094384A1 Use of interleukin 17e for the treatment of cancer |
| 09/14/2006 | WO2006094357A1 Flavonoid compounds and uses thereof |
| 09/14/2006 | WO2006094347A1 Bicyclic nucleosides and nucleotides as therapeutic agents |
| 09/14/2006 | WO2006094327A1 Pharmaceutical preparation for treating mycobacterial infections |
| 09/14/2006 | WO2006086707A3 Extracts of asteraceae containing reduced levels of phototoxic thiophene derivatives and methods for preparing same |
| 09/14/2006 | WO2006086464A3 Dihydroquinazolinones as 5ht modulators |
| 09/14/2006 | WO2006084176A3 Compounds and compositions as ppar modulators |
| 09/14/2006 | WO2006081172A3 Compounds and compositions as protein kinase inhibitors |
| 09/14/2006 | WO2006080017A3 Biologically active silver-coated proteins |
| 09/14/2006 | WO2006078593A3 Direct compression formulation and process |
| 09/14/2006 | WO2006077427A3 Antiviral drug combinations |
| 09/14/2006 | WO2006077139A3 Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same |
| 09/14/2006 | WO2006076097A3 Stable non-crystalline formulation comprising losartan |
| 09/14/2006 | WO2006073456A3 Anti-coronavirus compounds |
| 09/14/2006 | WO2006071848A3 Glycolipids and analogues thereof as antigens for nk t cells |
| 09/14/2006 | WO2006071759A3 Fluorescent pyrazine derivatives and methods of using the same in assessing renal function |
| 09/14/2006 | WO2006070325A3 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| 09/14/2006 | WO2006069186A3 Small molecule bcl-xl/bcl-2 binding inhibitors |
| 09/14/2006 | WO2006069153A3 Vitamin d receptor modulators |
| 09/14/2006 | WO2006067450A3 Modulator |
| 09/14/2006 | WO2006067445A3 Csf-1r kinase inhibitors |
| 09/14/2006 | WO2006066203A3 Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod) |
| 09/14/2006 | WO2006065888A3 Targeted iron chelator delivery system |
| 09/14/2006 | WO2006065820A3 Pyrimidine inhibitors of erk protein kinase and uses therof |
| 09/14/2006 | WO2006065335A3 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| 09/14/2006 | WO2006063819A3 Manufacture process of n-substituted salicylamides |
| 09/14/2006 | WO2006062876A3 Estrogen receptor modulators |
| 09/14/2006 | WO2006061336A3 Oral compositions for absorption of phosphorus compounds |
| 09/14/2006 | WO2006060535A3 Indole derivatives for use as ppar active compounds |
| 09/14/2006 | WO2006058023A3 Treatment of stroke with histamine h3 inverse agonists or histamine h3 antagonists |
| 09/14/2006 | WO2006055663A3 The use of novel antibacterial compounds |
| 09/14/2006 | WO2006053161A8 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
| 09/14/2006 | WO2006051290A3 Compounds for treating protein-kinase mediated disorders |
| 09/14/2006 | WO2006047452A3 Reactive 1,3’-crosslinked carbocyanines and their bioconjugates |
| 09/14/2006 | WO2006043153A3 Use of zinc and copper chelators for the treatment of viral diseases |
| 09/14/2006 | WO2006040151A8 Subsituted hydroxyethylamine compounds for treating alzheimer’s disease |
| 09/14/2006 | WO2006040113A3 Heterocyclic diamide insecticidal agents |
| 09/14/2006 | WO2006036813A3 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
| 09/14/2006 | WO2006036007A3 Modified-release preparation |
| 09/14/2006 | WO2006034495A3 Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects |
| 09/14/2006 | WO2006034337A3 Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
| 09/14/2006 | WO2006034296A3 Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof |
| 09/14/2006 | WO2006034187A3 Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| 09/14/2006 | WO2006033505A8 Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or cholic acid derivatives |
| 09/14/2006 | WO2006031883A3 Analysis of mhc-peptide binding interactions |
| 09/14/2006 | WO2006031788A3 Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols |
| 09/14/2006 | WO2006031719A3 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof |
| 09/14/2006 | WO2006029013A3 Topical dermatological formulations and use thereof |
| 09/14/2006 | WO2006023210A3 Gp132: mehods and compositions for treating cancer |
| 09/14/2006 | WO2006020684A3 Methods of regulating differentiation and treating of multiple myeloma |
| 09/14/2006 | WO2006019787A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/14/2006 | WO2006017861A3 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists |
| 09/14/2006 | WO2006017741A3 Radiation inducible iex-1 promoter |
| 09/14/2006 | WO2006016707A3 Pyrazolone compounds for treating cerebrovascular disorders |
| 09/14/2006 | WO2006012492A3 Compositions and methods for viscosupplementation |
| 09/14/2006 | WO2006011792A3 Antimicrobial peptides derived from cap18 |
| 09/14/2006 | WO2006010568A3 Substituted pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1 h,3h)-diones and -4(3h)-ones, pyrido[3',2':4,5]furo[3,2-d]pyrimidine-2,4(1 h,3h)-diones and -4(3h)-ones, and use thereof as inhibitors of tnf-alpha release |
| 09/14/2006 | WO2006009465A3 Composition comprising protein material and non-oxidizable fatty acid entities |
| 09/14/2006 | WO2006009438A3 Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies |
| 09/14/2006 | WO2006007444A2 CaMKII/CALCIUM CHANNEL BINDING-RELATED COMPOSITIONS AND METHODS |
| 09/14/2006 | WO2006003471A3 Process for the preparation of pramipexole by chiral chromatography |
| 09/14/2006 | WO2006001961A3 Compositions and methods relating to pyrimidine synthesis inhibitors |
| 09/14/2006 | WO2005115136A3 Transgenic models of alzheimer’s disease and uses thereof in the treatment of a variety of neurodegenerative diseases |
| 09/14/2006 | WO2005112923A3 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes |
| 09/14/2006 | WO2005109304A8 Small molecules and a pharmacophore model for inhibition of anthrax lethal factor |
| 09/14/2006 | WO2005105093A3 METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION |
| 09/14/2006 | WO2005086619A3 Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| 09/14/2006 | WO2005084710B1 Nanocell drug delivery system |
| 09/14/2006 | WO2005084301A3 Compositions and methods for treating diseases |
| 09/14/2006 | WO2005077091A8 Nicotinamide riboside kinase compositions and methods for using the same |
| 09/14/2006 | WO2005048932A3 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
| 09/14/2006 | WO2005037257A3 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases |
| 09/14/2006 | WO2005037215A3 Compositions and methods for enhancing cognitive function and synaptic plasticity |
| 09/14/2006 | WO2005019166A3 Method of targeting a therapeutic agent |
| 09/14/2006 | WO2004108066A3 Neuronal regeneration and compound administration methods |
| 09/14/2006 | WO2004094655A3 Modulation of telomere-initiated cell signaling |
| 09/14/2006 | WO2004073634A3 Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| 09/14/2006 | WO2004037192A3 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases |
| 09/14/2006 | WO2003089588A3 Novel molecules of the pyrin/nbs/lrr protein family and uses thereof |
| 09/14/2006 | US20060205967 Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates |
| 09/14/2006 | US20060205952 Aminocarbonyl naphthol derivative, cyanonaphthol derivative, and method for producing them |
| 09/14/2006 | US20060205951 New crystal modification of torasemide |